Preparing your results

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.

BACKGROUND: Salsalate, a nonacetylated prodrug of salicylate, has been shown to decrease blood glucose concentration in small studies. OBJECTIVE: To compare the efficacy and safety of salsalate at different doses in patients with type 2 diabetes. DESIGN: Parallel randomized trial with computer-generated randomization and centralized allocation. Patients and investigators, including those assessing outcomes and performing analyses, were masked to group assignment. ( registration number: NCT00392678) SETTING: 3 private practices and 14 universities in the United States. PATIENTS: Persons aged 18 to 75 years with fasting plasma glucose concentrations of 12.5 mmol/L or less (< or = 225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% treated by diet, exercise, and oral medication at stable doses for at least 8 weeks. INTERVENTION: After a 4-week, single-masked run-in period, patients were randomly assigned to receive placebo or salsalate in dosages of 3.0, 3.5, or 4.0 g/d for 14 weeks (27 patients each) in addition to their current therapy. MEASUREMENTS: Change in HbA1c was the primary outcome. Adverse effects and changes in measures of coronary risk and renal function were secondary outcomes. RESULTS: Higher proportions of patients in the 3 salsalate treatment groups experienced decreases in HbA1c levels of 0.5% or more from baseline (P = 0.009). Mean HbA1c changes were -0.36% (P = 0.02) at 3.0 g/d, -0.34% (P = 0.02) at 3.5 g/d, and -0.49% (P = 0.001) at 4.0 g/d compared with placebo. Other markers of glycemic control also improved in the 3 salsalate groups, as did circulating triglyceride and adiponectin concentrations. Mild hypoglycemia was more common with salsalate; documented events occurred only in patients taking sulfonylureas. Urine albumin concentrations increased in all salsalate groups compared with placebo. The drug was otherwise well tolerated. LIMITATION: The number of patients studied and the trial duration were insufficient to warrant recommending the use of salsalate for type 2 diabetes at this time. CONCLUSION: Salsalate lowers HbA1c levels and improves other markers of glycemic control in patients with type 2 diabetes and may therefore provide a new avenue for treatment. Renal and cardiac safety of the drug require further evaluation. PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

Pubmed ID: 20231565


  • Goldfine AB
  • Fonseca V
  • Jablonski KA
  • Pyle L
  • Staten MA
  • Shoelson SE
  • TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team


Annals of internal medicine

Publication Data

March 16, 2010

Associated Grants

  • Agency: NCRR NIH HHS, Id: M01 RR001032
  • Agency: NCRR NIH HHS, Id: M01 RR002635
  • Agency: NHLBI NIH HHS, Id: P50 HL83813
  • Agency: NIDDK NIH HHS, Id: U01 DK074556
  • Agency: NIDDK NIH HHS, Id: U01 DK074556-01
  • Agency: NIDDK NIH HHS, Id: U01 DK74556
  • Agency: NCRR NIH HHS, Id: UL1 RR025008
  • Agency: NCATS NIH HHS, Id: UL1 TR000454

Mesh Terms

  • Adolescent
  • Adult
  • Aged
  • Albuminuria
  • Blood Glucose
  • Diabetes Mellitus, Type 2
  • Double-Blind Method
  • Female
  • Gastrointestinal Diseases
  • Hemoglobin A, Glycosylated
  • Humans
  • Hypoglycemic Agents
  • Lipids
  • Male
  • Middle Aged
  • Prodrugs
  • Salicylates
  • Tinnitus
  • Young Adult